PharmaFocus Today – Page 29 – media

Million-RMB-worth CAR-T Drugs Miss Out on Health Insurance Negotiations for the Fourth Time

This morning, the much-anticipated on-site negotiations for the 2024 National Health Insurance Drug List adjustment concluded. According to First Financial News, CAR-T drugs have once again been absent from this round of negotiations, marking the fourth consecutive time they have not participated. “None of us appeared at the health insurance negotiation site,” a representative from a CAR-T company told First Financial News. The latest negotiations began on October 27, with 25 health insurance negotiation experts divided into five groups, negotiating and bidding for 162 types of drugs. The list of drugs under negotiation included commonly used medications for diabetes, hypertension, and infections, as well as medications for tumors and rare diseases. The final results of the on-site negotiations and bidding will be announced separately. Earlier, on August 27, the National Health Insurance Administration published a notice regarding the drug list adjustments for the 2024 National Basic Health Insurance, Work Injury ...
- Source: drugdu
- 81
- November 1, 2024
brain-computer interface only costs $5,000

In reality, the brain-computer interface is connected to your brain at one end, extracting your ideas from the dense and complex neuronal electrical signals, and connected to external devices such as computers or machinery at the other end, directly bypassing your body to turn ideas into control signals and further execute commands. It does not need to rely on the peripheral nerves and muscle systems of your limbs to directly establish direct information exchange between the brain center and external devices. Musk released a monkey for experiment in 2021. The monkey typed a line of words “I want to eat snacks” on the computer through mind operation. This is supported by brain-computer interface technology. The cochlear implant that helps the disabled to obtain sound is the most successful and most popular technology for brain-computer interface so far. Its principle is to convert sound signals into electrical signals and transmit them ...
- Source: drugdu
- 62
- November 1, 2024
the wind rises, accelerates, and accelerates again

The development story of tumor drugs is always so similar: the early stage may be endless suffering, but after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. This is the development of drugs for the treatment of small cell carcinoma (SCLC). SCLC was first discovered about 100 years ago, but it was not until 1968 that the medical community discovered its neuroendocrine origin and finally clearly distinguished it from other lung cancers. In the 1980s, the treatment of platinum-containing chemotherapy combined with chest radiotherapy gradually became clear and became the basic treatment for small cell lung cancer. Although the combination of etoposide and carboplatin/cisplatin (EP) has been the standard treatment for SCLC until now; but we can also clearly see that the battle against small cell lung cancer has entered an accelerated stage. In May of this year, Amgen’s DLL3/CD3 dual antibody Tarlatamab ...
- Source: drugdu
- 90
- November 1, 2024
Medtronic announces a Chief Medical Officer from Cleveland Medical Center

On October 28, 2024, Medtronic announced the appointment of Dr. Matthew Kroh as Chief Medical Officer for Advanced and General Surgery Technologies. Dr. Matthew Crowe is the Vice President of Innovation and Technology at the Cleveland Clinic Digestive Disease and Surgery Institute. He is the director of the Department of General Surgery, Endoscopic Surgery, and Foreintestinal Surgery. 01. Surgical Laparoscopic Specialist at Cleveland Medical Center Cleveland Clinic is one of the world’s most renowned medical institutions, founded on February 28, 1921. In the 2017-2018 ranking of the best hospitals in the United States, Cleveland Clinic ranked second overall, only behind Mayo Clinic. Among them, cardiac surgery and urology are ranked first in the United States; General surgery, rheumatology, and nephrology rank second. Dr. Matthew Crowe is from Cleveland Medical Center. According to the official website of the Cleveland Clinic, Dr. Matthew Crowe is the Vice President of Innovation and Technology ...
- Source: drugdu
- 62
- October 31, 2024
The hearing aid industry has a huge gap

In the current Chinese medical device industry, competition is extremely fierce, and many fields have become saturated, making it difficult to find new growth points or development space. But this set of data shows that there is a huge resource gap in the intervention of hearing loss in the elderly population in China. According to the “China Elderly Hearing Loss and Hearing Aid Application Survey” released by Tmall Health, Beijing Hearing Association, and Sonova Group, there is one professional hearing service provider for every 90000 people in China, which is much lower than the United States (9000:1). This huge gap not only reflects the scarcity of human resources allocation in this field in China, but also reflects the large scale of the population with hearing loss. 1. There are 120 million elderly people with hearing loss, and the wearing rate of hearing aids is less than 5% Hearing loss is ...
- Source: drugdu
- 65
- October 31, 2024
Consumables traceability code will be rolled out nationwide

Today (October 29) at 9:00 am, the National Medical Insurance Bureau held a national medical insurance drug and consumables traceability information collection and application release interpretation activities. At the Cyber Blue Medical Device Conference, it was learned that as of October 28, 32 provincial medical insurance information platforms have fully carried out the collection of drug and consumables traceability codes, and 3.127 billion drug and consumables traceability code data have been collected, involving 296,800 designated medical institutions and 497,200 designated retail pharmacies. More than 60% of medical institutions and 99% of pharmacies have carried out the collection of traceability codes. The National Medical Insurance Bureau has made it clear that it will continue to promote the application of drug and consumables traceability codes in the future, so that every link of drug and consumables from production, transportation to sales can be monitored and recorded in a timely manner, and use ...
- Source: drugdu
- 80
- October 31, 2024
The third day of the national negotiations! Oncology drugs and traditional Chinese medicines are on display, Pfizer, China Resources Sanjiu, Jianmin, Dizhe…

On October 29, the 2024 national negotiations entered the third day, and a group of companies such as Yangtze River, Yiling, China Resources Sanjiu, Jichuan, and Jianmin took their traditional Chinese medicine varieties to the stage. Before entering the venue in the afternoon, the overall atmosphere on the scene was relatively relaxed. When the staff of the Medical Insurance Bureau called the roll, some company representatives did not respond in time. Other company representatives joked, “Okay, automatically give up,” and everyone laughed. At the scene, many representatives of traditional Chinese medicine companies showed strong confidence in their products, and mentioned the advantages of traditional Chinese medicine over chemical medicine in the treatment of the same disease during the conversation. At the same time, this year’s national negotiations focus on “high-quality, cost-effective innovation” and also apply to traditional Chinese medicine. A representative of a traditional Chinese medicine company with exclusive varieties ...
- Source: drugdu
- 70
- October 31, 2024
Hengrui Medicine plans to be listed on the Hong Kong Stock Exchange?

According to overseas media Bloomberg, Jiangsu Hengrui Medicine Co., Ltd. is considering a second listing in Hong Kong next year. People familiar with the matter said that the company is discussing potential share sales with consultants, which may raise at least US$2 billion (about HK$15.5 billion). This news has attracted widespread attention. In response, Hengrui Medicine said that it “would not comment” on the rumor.Affected by this news, Hengrui Medicine’s stock price has fluctuated significantly, and its current market value is about RMB 300 billion (US$43 billion). In recent years, “A+H” stocks have continued to expand. With the listing of Midea Group on the Hong Kong Stock Exchange on September 17, there are currently 150 companies that have successfully achieved “A+H” dual listings. Among them are many biopharmaceutical companies, including innovative pharmaceutical companies: Innovent Biologics, Fudan Zhangjiang, CanSino Biologics, Rongchang Bio, Junshi Biosciences, BeiGene, etc., traditional pharmaceutical companies: Shanghai Pharmaceuticals, ...
- Source: drugdu
- 81
- October 31, 2024
Huiyu Pharmaceuticals was the first company to pass the review for its “Detoxification Injection”

From October 14 to October 20, a total of 59 varieties passed/are deemed to have passed the consistency evaluation. During the same period, 88 varieties applied for consistency evaluation. Huiyu Pharmaceutical: Acetylcysteine Injection According to the official website of NMPA, Huiyu Pharmaceutical’s acetylcysteine injection was approved for marketing on October 16. The specifications approved this time are: 30ml: 6g, and the indications are detoxification of acute acetaminophen poisoning, used to prevent or alleviate liver damage caused by its overdose. Acetylcysteine is a precursor of reduced glutathione (GSH) and is an oxygen free radical scavenger in the body. The mechanism of its liver protection is still unclear, and may be related to maintaining or restoring glutathione levels. In addition, acetylcysteine may also play a liver protection role by improving hemodynamics and oxygen transport capacity and expanding microcirculation. As of now, Huiyu Pharmaceutical’s acetylcysteine injection is the first and only product of ...
- Source: drugdu
- 67
- October 31, 2024
GE Healthcare, this product is being produced for the first time in the United States

Recently, GE Healthcare is manufacturing the integrated Omni Legend PET/CT at its new production facility in Wisconsin. This marks the first time that the system has been produced domestically in the United States. 01. Innovative product Omni Legend PET/CT GE HealthCare launched its first PET/CT: Omni Legend on the fully digital Omni platform at the European Association for Nuclear Medicine (EANM) annual meeting in October 2022. The system achieved significant improvements in sensitivity, efficiency, radiation dose, and patient comfort. The system is equipped with a new digital BGO (dBGO) detector, aimed at improving examination efficiency, enhancing patient experience, and boosting diagnostic confidence. The system adopts a new category of digital BGO (dBGO) detector materials, with small crystal size and sensitivity more than twice that of existing digital scanners, which can achieve faster total scanning time and impressive small lesion detectability It aims to improve operational efficiency, enhance patient experience, and ...
- Source: drugdu
- 75
- October 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.